During the corresponding time, Cumberland Pharmaceuticals Inc saw a revenue deteriorated by -98.46 % year on year, sequentially revenue fell by -98.18 %. While revenue at the Cumberland Pharmaceuticals Inc 's corporate clients
Cumberland Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company provides treatments for patients with conditions including chemotherapy-induced nausea and vomiting (CINV), hyponatremia, and other critical care disorders. Its market segments include oncology patients undergoing chemotherapy, hospitalized patients with euvolemic and hypervolemic hyponatremia, and critical care patients experiencing electrolyte disturbances related to congestive heart failure, liver failure, kidney failure, and pneumonia. The company supports Kristalose through its field sales division and partnerships with Poly Pharmaceuticals and Foxland Pharmaceuticals, Inc. It markets Sancuso, an FDA-approved prescription patch for CINV, via its Cumberland Oncology sales division, targeting healthcare professionals treating cancer patients. Vaprisol, indicated for increasing serum sodium levels in hospitalized hyponatremic patients, is promoted by the hospital sales division and used in hospitals and clinics, particularly during the pandemic. The company assumed full commercial responsibility for Sancuso in the U.S. after acquiring rights from Kyowa Kirin, which retains international rights.
Cumberland Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company provides treatments for patients with conditions including chemotherapy-induced nausea and vomiting (CINV), hyponatremia, and other critical care disorders. Its market segments include oncology patients undergoing chemotherapy, hospitalized patients with euvolemic and hypervolemic hyponatremia, and critical care patients experiencing electrolyte disturbances related to congestive heart failure, liver failure, kidney failure, and pneumonia. The company supports Kristalose through its field sales division and partnerships with Poly Pharmaceuticals and Foxland Pharmaceuticals, Inc. It markets Sancuso, an FDA-approved prescription patch for CINV, via its Cumberland Oncology sales division, targeting healthcare professionals treating cancer patients. Vaprisol, indicated for increasing serum sodium levels in hospitalized hyponatremic patients, is promoted by the hospital sales division and used in hospitals and clinics, particularly during the pandemic. The company assumed full commercial responsibility for Sancuso in the U.S. after acquiring rights from Kyowa Kirin, which retains international rights.
Sources:
Cumberland Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cumberland Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cumberland Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2569.88 %